121 related articles for article (PubMed ID: 29515235)
1. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.
Rodríguez-Otero P; Mateos MV; Martínez-López J; Martín-Calvo N; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Bargay J; Bengoechea E; González Y; de Oteyza JP; Gironella M; Encinas C; Martín J; Cabrera C; Palomera L; de Arriba F; Cedena MT; Paiva B; Puig N; Oriol A; Bladé J; Lahuerta JJ; San Miguel JF
Leukemia; 2018 Nov; 32(11):2427-2434. PubMed ID: 29515235
[TBL] [Abstract][Full Text] [Related]
2. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.
Gu Y; Yuan YH; Xu J; Shi QL; Qu XY; Guo R; Bai H; Xu JD; Li JY; Chen LJ
Oncotarget; 2017 Jul; 8(29):48350-48361. PubMed ID: 28418851
[TBL] [Abstract][Full Text] [Related]
3. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.
Corso A; Galli M; Mangiacavalli S; Rossini F; Nozza A; Pascutto C; Montefusco V; Baldini L; Cafro AM; Crippa C; Cazzola M; Corradini P
Am J Hematol; 2012 Feb; 87(2):150-4. PubMed ID: 22189759
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
5. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
Encinas C; Hernandez-Rivas JÁ; Oriol A; Rosiñol L; Blanchard MJ; Bellón JM; García-Sanz R; de la Rubia J; de la Guía AL; Jímenez-Ubieto A; Jarque I; Iñigo B; Dourdil V; de Arriba F; Pérez-Ávila CC; Gonzalez Y; Hernández MT; Bargay J; Granell M; Rodríguez-Otero P; Silvent M; Cabrera C; Rios R; Alegre A; Gironella M; Gonzalez MS; Sureda A; Sampol A; Ocio EM; Krsnik I; García A; García-Mateo A; Soler JA; Martín J; Arguiñano JM; Mateos MV; Bladé J; San-Miguel JF; Lahuerta JJ; Martínez-López J;
Blood Cancer J; 2022 Apr; 12(4):68. PubMed ID: 35440057
[TBL] [Abstract][Full Text] [Related]
6. Geriatric Assessment Predicts Survival and Competing Mortality in Elderly Patients with Early Colorectal Cancer: Can It Help in Adjuvant Therapy Decision-Making?
Antonio M; Saldaña J; Carmona-Bayonas A; Navarro V; Tebé C; Nadal M; Formiga F; Salazar R; Borràs JM
Oncologist; 2017 Aug; 22(8):934-943. PubMed ID: 28487465
[TBL] [Abstract][Full Text] [Related]
7. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F; Kastritis E; Zomas A; Terpos E; Katodritou E; Symeonidis A; Delimpasi S; Pouli A; Vassilakopoulos TP; Michalis E; Giannouli S; Kartasis Z; Christoforidou A; Kokoviadou K; Hatzimichael E; Gika D; Megalakaki C; Papaioannou M; Kyrtsonis MC; Konstantopoulos K; Dimopoulos MA;
Eur J Haematol; 2017 Nov; 99(5):409-414. PubMed ID: 28675766
[TBL] [Abstract][Full Text] [Related]
9. Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
Chim CS; Liu H; Lie AK; Chan EY; Ho S; Wong M; Kwong YL
Hematol Oncol; 2014 Dec; 32(4):205-11. PubMed ID: 24473998
[TBL] [Abstract][Full Text] [Related]
10. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma in elderly patients: prognostic factors and outcome.
Anagnostopoulos A; Gika D; Symeonidis A; Zervas K; Pouli A; Repoussis P; Grigoraki V; Anagnostopoulos N; Economopoulos T; Maniatis A; Dimopoulos MA
Eur J Haematol; 2005 Nov; 75(5):370-5. PubMed ID: 16191085
[TBL] [Abstract][Full Text] [Related]
12. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
Paiva B; Vídriales MB; Montalbán MÁ; Pérez JJ; Gutiérrez NC; Rosiñol L; Martínez-López J; Mateos MV; Cordón L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Sureda A; Gorosquieta A; Alegre A; Martin A; Lahuerta JJ; Bladé J; Orfao A; San Miguel JF
Am J Pathol; 2012 Nov; 181(5):1870-8. PubMed ID: 22974582
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
15. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myeloma.
Smith ML; Newland AC
QJM; 1999 Jan; 92(1):11-4. PubMed ID: 10209667
[TBL] [Abstract][Full Text] [Related]
18. Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice.
Xia J; Wang L; Zhou X; Wang J; Wang H; Guo H
J Int Med Res; 2018 Jun; 46(6):2230-2237. PubMed ID: 29584537
[TBL] [Abstract][Full Text] [Related]
19. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.
Mellors PW; Binder M; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Zeldenrust SR; Lust JA; Leung N; Go RS; Kyle RA; Vincent Rajkumar S; Kumar SK
Am J Hematol; 2018 Jul; 93(7):889-894. PubMed ID: 29659048
[TBL] [Abstract][Full Text] [Related]
20. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
